Home › Bipolar Disorder › Oklahoma › Oklahoma City
Bipolar Disorder clinical trials in Oklahoma City, OK
3 studies for Bipolar Disorder are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RecruitingPhase 3
- Sooner Clinical Research, Oklahoma City
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
RecruitingPhase 3
- SP Research, PLLC (dba Rivus Wellness & Research Institute), Oklahoma City
- Sooner Clinical Research, Oklahoma City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RecruitingPhase 2
- Sooner Clinical Research /ID# 272856, Oklahoma City
About Bipolar Disorder
Bipolar disorder is a mood disorder that can cause intense mood swings. It's also called manic depression. Learn about the types, symptoms, treatment, and more.
More about Bipolar Disorder on MedlinePlus
Bipolar Disorder trials in other cities
- Houston, TX10 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Little Rock, AR6 studies
- Atlanta, GA6 studies
- Hialeah, FL5 studies
- Miami, FL5 studies
- Austin, TX5 studies
- Cambridge, MA5 studies
- Orange, CA5 studies
- West Palm Beach, FL4 studies
- O'Fallon, MO4 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer15 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Pancreatic Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.